<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pegunigalsidase alfa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pegunigalsidase alfa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pegunigalsidase alfa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141501" href="/d/html/141501.html" rel="external">see "Pegunigalsidase alfa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58227114"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions including anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with pegunigalsidase alfa have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during pegunigalsidase alfa administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue pegunigalsidase alfa immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to pegunigalsidase alfa may be considered.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58290898"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elfabrio</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58227135"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F58246561"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider premedication with an antipyretic (eg, acetaminophen), antihistamines (eg, diphenhydramine), and/or corticosteroids (eg, prednisone) in patients who are enzyme replacement therapy (ERT)–naive or who are ERT-experienced but previously required pretreatment medications. After 4 to 6 infusions, a stepwise decrease in pretreatment medication dose(s) and/or discontinuation of pretreatment medication(s) may be considered in patients tolerating treatment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2806c8e7-5d91-4e7a-86c0-5f6f8f68f985">Fabry disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fabry disease: IV:</b> 1 mg/kg every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses</i>
<i>: </i>If ≥1 dose is missed, administer the missed dose as soon as possible and restart the 2-week interval.</p></div>
<div class="block dora drugH1Div" id="F58246563"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Membranoproliferative glomerulonephritis:</i> Discontinue pegunigalsidase alfa.</p></div>
<div class="block doha drugH1Div" id="F58246564"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F58246565"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity or infusion reaction, mild to moderate: </b>Consider temporarily holding infusion for 15 to 30 minutes or slowing the infusion rate by 25% to 50%; institute appropriate medical treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If symptoms persist after initially holding or slowing infusion rate: </i>Discontinue the infusion and monitor the patient; consider reinitiating the infusion within 7 to 14 days at 25% to 50% of the rate at which the reaction occurred with appropriate pretreatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If symptoms subside after initially holding the infusion:</i> Resume infusion at a 25% to 50% reduced rate as tolerated. Starting with the next infusion, increase the infusion rate in increments of 25% every third infusion as tolerated until the infusion rate at which the reaction occurred is reached; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If symptoms subside after initially reducing the infusion rate: </i>Complete infusion at the reduced rate as tolerated. Starting with the next infusion, increase the infusion rate in increments of 25% every third infusion as tolerated until the infusion rate at which the reaction occurred is reached; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity (eg, anaphylaxis) or infusion reaction, severe:</b> Immediately discontinue pegunigalsidase alfa and institute appropriate medical treatment. Consider the risks and benefits of readministering pegunigalsidase alfa; patients may be rechallenged using slower infusion rates or desensitization measures.</p></div>
<div class="block doe drugH1Div" id="F58246562"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58899684"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Type 1 <b>hypersensitivity reaction</b>, including <b>anaphylaxis</b> and <b>severe hypersensitivity reaction</b>, have been reported with pegunigalsidase alfa. Signs and symptoms of hypersensitivity included airway obstruction, angioedema, bronchospasm, headache, hypotension, macroglossia, nausea, pruritus, rash, rigors, tachycardia, throat tightness, urticaria, and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immediate allergic hypersensitivity reactions (eg, anaphylaxis) are typically IgE mediated; delayed-type reactions may be T-cell mediated or antibodies other than IgE (eg, IgG mediated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34502086','lexi-content-ref-EMA.2017','lexi-content-ref-FDA.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34502086','lexi-content-ref-EMA.2017','lexi-content-ref-FDA.2014'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; anaphylaxis occurred within 5 to 40 minutes after infusion initiation; other hypersensitivity reactions including rash and face swelling may occur up to 24 hours after infusion completion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting anti-drug antibodies from prior enzyme replacement therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Anti–pegunigalsidase alfa-iwxj IgE antibodies</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher infusion rates</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reaction</b> (IRR) has been reported with pegunigalsidase alfa. Most IRRs were mild to moderate, although serious reactions were also reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bernat.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bernat.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; has been reported after the start of the infusion and extending up to 24 hours after completion of infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• IgG or IgE anti-drug antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bernat.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bernat.2022'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting anti-drug antibodies from prior enzyme replacement therapy</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F58234597"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in enzyme replacement therapy (ERT)-experienced adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (12%), diarrhea (19%), nausea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (9% to 14%; including anaphylaxis and severe hypersensitivity reaction)<span class="lexi-table-link-container"> (<a aria-label="Hypersensitivity Reaction table link" class="lexi-table-link" data-table-id="lexi-content-hypersensitivity-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypersensitivity-reaction')">table 1</a>)</span><span class="table-link" style="display:none;">Hypersensitivity Reaction</span>, infusion-related reaction (29% to 32%)<span class="lexi-table-link-container"> (<a aria-label="Infusion-Related Reaction table link" class="lexi-table-link" data-table-id="lexi-content-infusion-related-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infusion-related-reaction')">table 2</a>)</span><span class="table-link" style="display:none;">Infusion-Related Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypersensitivity Reaction" frame="border" id="lexi-content-hypersensitivity-reaction" rules="all">
<caption style="text-align:center;">
<b>Pegunigalsidase Alfa: Adverse Reaction: Hypersensitivity Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pegunigalsidase Alfa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Agalsidase Beta)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pegunigalsidase Alfa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Agalsidase Beta)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="nfusion-Related Reaction" frame="border" id="lexi-content-nfusion-related-reaction" rules="all">
<caption style="text-align:center;">
<b>Pegunigalsidase Alfa: Adverse Reaction: Infusion-Related Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pegunigalsidase Alfa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Agalsidase Beta)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pegunigalsidase Alfa)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Agalsidase Beta)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (females: 13% [neutralizing: 4%]; males: 59% [neutralizing: 48%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (17%), headache (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (15%), limb pain (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (21%), sinusitis (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuralgia (8%), peripheral neuropathy (6%), sciatica (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Membranoproliferative glomerulonephritis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory congestion (upper respiratory tract: 8%)</p></div>
<div class="block coi drugH1Div" id="F58227117"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58246543"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of IgG anti-drug antibodies may occur and has been observed within 26 weeks from the onset of therapy. Patients who have received prior enzyme replacement therapy are more likely to have preexisting anti-drug antibodies, which may reduce pegunigalsidase alfa efficacy and increase the risk for hypersensitivity and infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis (occurring within 5 to 40 minutes of the initial infusion), have been reported with pegunigalsidase alfa use. Signs and symptoms of hypersensitivity have included airway obstruction, angioedema, bronchospasm, headache, hypotension, macroglossia, nausea, pruritus, rash, rigors, tachycardia, throat tightness, urticaria, and vomiting. Patients who develop IgE antibodies may be at a higher risk for hypersensitivity reactions. Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion-related reactions (eg, abdominal pain, agitation, bradycardia, burning sensation, chest pain, chills, diarrhea, dizziness, dyspnea, erythema, fever, flushing, headache, hypertension, hypotension, myalgia, nasal congestion, nausea, neuralgia, pain, paresthesia, pruritus, rash, sneezing, throat irritation, tremor, weakness, vomiting) may occur at onset of infusion and up to 24 hours after the end of the infusion. Patients who develop IgG antibodies may be at a higher risk for infusion reactions. Reactions were usually managed with antipyretics, antihistamines, corticosteroids, IV fluids, and/or oxygen. Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids. Infusion reactions have occurred despite premedication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Membranoproliferative glomerulonephritis: Membranoproliferative glomerulonephritis with immune deposits in the kidney leading to decreased renal function has been reported. Renal function slowly improved upon discontinuation but did not return to baseline.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Patients with advanced Fabry disease may have compromised cardiac function and be at increased risk of complications from infusion reactions.</p></div>
<div class="block foc drugH1Div" id="F58290899"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elfabrio: Pegunigalsidase alfa-iwxj 20 mg/10 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F58290897"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58318466"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Elfabrio Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/10 mL (per mL): $521.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F58246566"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse through a low protein-binding 0.2-micron in-line filter. See tables for initial infusion rates for the first 4 to 6 infusions. After the initial 4 to 6 infusions, the duration of every third infusion may be decreased in decrements of 30 minutes as tolerated; minimum infusion rate is 1.5 hours. After administration, flush infusion line with NS using the same infusion rate used for the last part of the pegunigalsidase infusion. Health care providers may consider home infusion in patients reaching an infusion duration that is well tolerated; infusion duration should remain constant and rate changes should only occur in a health care facility.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommended Initial (First 4 to 6 Infusions) Infusion Rates for Enzyme Replacement Therapy–Experienced Patients</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">
<b>Patient weight (actual body weight)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Infusion rate<sup>a,b</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> Infusion rate may be increased if the patient tolerates the initial 4 to 6 infusions or may be reduced if hypersensitivity or infusion reaction occurs.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>b</sup> In patients previously treated with an enzyme replacement therapy infusion duration over 3 hours, use the same initial infusion rate for the pegunigalsidase infusion; may decrease duration of every third infusion in decrements of 30 minutes as tolerated.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;70 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.83 mL/minute</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">70 to 100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.39 mL/minute</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2.78 mL/minute</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommended Initial (First 4 to 6 Infusions) Infusion Rates for Enzyme Replacement Therapy–Naive Patients</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">
<b>Patient weight (actual body weight)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Infusion rate<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> Infusion rate may be increased if the patient tolerates the initial 4 to 6 infusions or may be reduced if hypersensitivity or infusion reaction occurs.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;70 kg</p></td>
<td align="center">
<p style="text-indent:0em;">0.63 mL/minute</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">70 to 100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1 mL/minute</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1.38 mL/minute</p></td></tr></tbody></table></div>
<div class="block use drugH1Div" id="F58227116"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Fabry disease:</b> Enzyme replacement therapy for adults with confirmed Fabry disease (Anderson-Fabry disease).</p></div>
<div class="block mst drugH1Div" id="F58246540"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pegunigalsidase alfa may be confused with pegaspargase or pegloticase.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58246398"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58246395"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F58246541"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in reproduction studies conducted in rats using doses 3.6 times the recommended human dose; maternal toxicity was observed in rabbit studies using doses 6.5 times the recommended dose. Adverse events in humans would not be expected when used for enzyme replacement therapy.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to pegunigalsidase alfa is ongoing. Health care providers are encouraged to enroll patients exposed to pegunigalsidase alfa during pregnancy in the safety study (1-888-661-9260 or https://chiesirarediseases.com/contact-us/medicalinformation-form).</p></div>
<div class="block brc drugH1Div" id="F58246542"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pegunigalsidase alfa is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F58246568"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine and urinary protein to creatinine ratio; signs and symptoms of hypersensitivity and infusion reactions (especially in patients with compromised cardiac function); presence of IgG and IgE anti-pegunigalsidase alfa antibodies in patients developing hypersensitivity or infusion reactions.</p></div>
<div class="block pha drugH1Div" id="F58246556"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pegunigalsidase alfa is a recombinant form of the enzyme alpha-galactosidase-A, which catalyzes the hydrolysis of globotriaosylceramide (Gb-3), cleaving a terminal galactose residue from the molecule. Accumulation of globotriaosylceramide (Gb-3) may occur within the tissues of patients with Fabry disease. Pegunigalsidase alfa is internalized and transported into lysosomes exerting enzymatic activity and reducing cellular levels of Gb-3.</p></div>
<div class="block phk drugH1Div" id="F58246557"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Mean range: 95 to 392 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean range: 57.3 to 143 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Mean range: 1 to 3.6 mL/hour/kg.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Bernat.2022">
<a name="Bernat.2022"></a>Bernat J, Holida M, Goker-Alpan O, et al. Tolerability and infusion duration of pegunigalsidase alfa in patients with Fabry Disease: Data from 5 completed clinical trials. Poster presented at: 7th Update on Fabry Disease; May 29-31, 2022; Würzberg, Germany.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34502086">
<a name="34502086"></a>de la Fuente M, Lombardero L, Gómez-González A, et al. Enzyme therapy: Current challenges and future perspectives. <i>Int J Mol Sci</i>. 2021;22(17):9181. doi:10.3390/ijms22179181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegunigalsidase-alfa-drug-information/abstract-text/34502086/pubmed" id="34502086" target="_blank">34502086</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Elfabrio (pegunigalsidase alfa) [prescribing information]. Cary, NC: Chiesi USA; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.2017">
<a name="EMA.2017"></a>European Medicines Agency: Science Medicines Health. Guideline on immunogenicity assessment of therapeutic proteins. 2017; EMEA/CHMP/BMWP/14327/2006 Rev1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2014">
<a name="FDA.2014"></a>Food and Drug Administration. Center for Drug Evaluation and Research (CDER); Center for Biologics Evalution and Research (CBER). Guideline for Industry: Immunogenicity assessment for therapeutic protein products. August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30834538">
<a name="30834538"></a>Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. <i>J Inherit Metab Dis</i>. 2019;42(3):534-544. doi:10.1002/jimd.12080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegunigalsidase-alfa-drug-information/abstract-text/30834538/pubmed" id="30834538" target="_blank">30834538</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141472 Version 14.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
